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Abstract
Background
We evaluated the associations of handgrip strength and cognitive function in cancer survi-
vors 60 years old using data from the National Health and Nutrition Examination Survey
(NHANES).
Methods
Data in two waves of NHANES (2011–2014) were aggregated. Handgrip strength in kilo-
gram (kg) was defined as the maximum value achieved using either hand. Two cognitive
function tests were conducted among adults 60 years and older. The Animal Fluency Test
(AFT) examines categorical verbal fluency (a component of executive function), and the Dig-
ital Symbol Substitution test (DSST) assesses processing speed, sustained attention, and
working memory. Survey analysis procedures were used to account for the complex sam-
pling design of the NHANES. Multiple linear regression models were used to estimate asso-
ciations of handgrip strength with cognitive test scores, adjusting for confounders (age,
gender, race/ethnicity, education, marital status, smoking status, depressive symptoms and
leisure time physical activity).
Results
Among 383 cancer survivors (58.5% women, mean age = 70.9 years, mean BMI = 29.3 kg/
m2), prevalent cancer types were breast (22.9%), prostate (16.4%), colon (6.9%) and cervix
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(6.2%). In women, each increase in kg of handgrip strength was associated with 0.20 (95%
CI: 0.08 to 0.33) higher score on AFT and 0.83 (95% CI: 0.30 to 1.35) higher score on
DSST. In men, we observed an inverted U-shape association where cognitive function
peaked at handgrip strength of 40–42 kg.
Conclusions
Handgrip strength, a modifiable factor, appears to be associated with aspects of cognitive
functions in cancer survivors. Prospective studies are needed to address their causal
relationship.
Introduction
Cancer- and cancer treatment-related cognitive impairments are prevalent among cancer sur-
vivors [1]. Recent data have shown that detectable cognitive impairments are more prevalent
in cancer survivors than aged matched cancer-free controls. The prevalence of cognitive
impairment among cancer survivors is approximately 30% before cancer treatments, and up to
75% during- and approximately 35% post-cancer treatments [2]. This phenomenon is worse
in older cancer survivors possibly owing to lower physical and cognitive reserves compared to
younger survivors [1].
The modalities of preventing and treating cancer- and cancer-treatment related cognitive
impairments are lacking because its aetiology is not well understood [2]. In addition, among
factors that are thought to play aetiological roles, many are non-modifiable, such as host char-
acteristics, immune dysfunction, cancer therapy induced neural toxicity, and genetics [2].
Recently, low serum level of brain-derived neurotrophic factor (BDNF) [3] was found to be
associated cognitive impairments, and genetic variations in the BDNF gene [4] were found to
protect against cognitive impairments in cancer patients receiving chemotherapy.
These findings are promising as BNDF is a neurotrophin, secreted in responses to muscle
contraction [5]. Furthermore, muscle strength, which measures the exertion of muscle con-
traction, is positively related to serum BDNF concentration [6]. Meanwhile, muscle dysfunc-
tion, characterised by impairments in muscle strength or muscle composition, is common in
cancer survivors [7]. However, the association between muscle function and cognitive function
in cancer survivors is unknown.
To address this gap, we evaluated for the first time the cross-sectional associations of hand-
grip strength with two cognitive function outcomes among cancer survivors, using data from
the National Health and Nutrition Examination Survey (NHANES).
Methods
Study population
The National Health and Nutrition Examination Survey (NHANES) was designed to provide
cross-sectional estimates on the prevalence of health, nutrition, and potential risk factors
among the civilian non-institutionalized U.S. population up to 85 years of age [8]. In brief,
NHANES surveys a nationally representative complex, stratified, multistage, probability clus-
tered sample of about 5,000 participants each year in 15 counties across the country. Survey
participants were asked to attend physical examination in a mobile examination center
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(MEC). The NHANES obtained approval from the National Center for Health Statistics
Research Ethics Review Board and participants provided written consent.
We extracted and aggregated data on handgrip strength, cognitive function test scores,
other characteristics and cancer diagnosis from NHANES in 2011 to 2012, and 2013 to 2014.
We excluded those who were never diagnosed with cancer. All NHANES data were fully anon-
ymized before access and analysis for this study.
Cancer diagnosis
Participants were considered to be cancer survivors if the answered affirmatively to the ques-
tion “Have you ever been told by a doctor or other health professional that you had cancer or a
malignancy of any kind?” We excluded participants who had non-melanoma skin cancer.
Cognitive functioning test
Data on two cognitive function tests, the Animal Fluency Test (AFT) and the Digital Symbol
Substitution test (DSST), were extracted, assessing the most commonly reported cognitive
impairments in cancer survivors: executive function (working memory), and attention and
concentration (processing speed) [1]. Both tests have been widely used in large-scale screen-
ings, epidemiological and clinical studies [9–11]. For each test, cognitive function was evalu-
ated by a score that summarizes the total number of correct answers within a given time
period. AFT examines categorical verbal fluency, a component of executive function. The task
in AFT asked participants to name as many animals as possible in one minute, where the total
number of named animals was summarized as the test score (age-adjusted cut-offs for cogni-
tive impairment: 65–74 years old: 15; 75–79 years old: [14]). DSST is a performance module
from the Wechsler Adult Intelligence Scale (WAIS III), assessing processing speed, sustained
attention and working memory [12]. Task in the DSST provided each participant a paper form
that has a key at the top containing 9 numbers paired with symbols. Then participants were
asked to copy the corresponding symbols in the 133 boxes that adjoin the numbers in two
minutes, where the total number of correct matches was summarized as the test score (maxi-
mum score is 133 points). The cognitive function tests were administered to participants aged
60 years and older, only.
Handgrip strength
The handgrip strength test protocol is detailed in the NHANES Muscle Strength Procedures
Manual [13]. Participants did not perform handgrip strength tests if they were unable to hold
the dynamometer with both hands for reasons including: missing both arms, both hands,
thumbs on both hands, or paralyzed in both hands. Other reason for not performing the test
included had no time, arrived late or left early, refusal, illness, emergency or equipment fail-
ures. In brief, handgrip strength in kilogram (kg) was measured with the Takei Digital Grip
Strength Dynamometer over three trials separately by 60 seconds and alternating hands. Par-
ticipants were asked to squeeze the dynamometer for a practice trial using submaximal effort
to determine their understandings on the procedure and the grip size adjustments. They were
randomly assigned to start the test with their dominant or non-dominant hand. To complete
the test, participants were asked to use one hand to squeeze the dynamometer as hard as possi-
ble, and repeat using the other hand for a total of three alternating hands. Similar to previous
studies using this measure, we extracted the maximum value achieved using either hand as the
summary measure [14]. Studies have retrieved consistent results irrespective of using maxi-
mum or average values [15]. We classified cancer survivors as sarcopenic based on the hand-
grip strength criteria (men<30 kg; women <20 kg) [16].
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Socio-demographic characteristics
Data on age, sex, race and ethnicity, education and smoking status were extracted. Based on
self-reported race and ethnicity, participants were classified into one of the three racial/ethnic
groups: Non-Hispanic White, Non-Hispanic Black, and Hispanic and others. Participant’s
education levels were classified into four groups: less than high school, high school, some col-
lege, and college graduate or above. Marital status was summarized into two groups: live with
someone (married, and living with partner), and live alone (widowed, divorced, separated,
never married). Finally, we classified participants into three smoking groups: never smokers
(did not smoke 100 cigarettes in life and do not smoke now), former smokers (smoked 100 cig-
arettes in life and do not smoke now), and current smokers (smoked 100 cigarettes in life and
smoke now).
Body mass index (BMI)
Weight and height were measured at the time of physical examination in the MEC. The mea-
surements followed standard procedures and were carried out by trained technicians using
standardized equipment. BMI was calculated as weight in kg/(height in meters)2, and catego-
rized into standard BMI categories: underweight (<18.5kg/m2), normal weight (18.5 to<25
kg/m2), overweight (25 to<30 kg/m2), and obese (30.0 kg/m2). For analytic purposes, we
combined underweight and normal weight (<25 kg/m2).
Depressive symptoms
Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-9), a valid
9-item depression screener asking about the frequency of symptoms of depression over the
past 2 weeks [17]. Each item was scored on a 0–3 scale. The total score of FHQ-9 ranged from
0 to 27, and were categorised as “none or minimum” (0–4), “mild” (5–9), “moderate” (10–14),
“moderately severe” (15–19), and “severe” (20–27) for depression severity. For current analy-
ses, participants who scored 10 or more were combined into one group as clinically relevant
depression, such diagnosis has shown a sensitivity of 88% and a specificity of 88% for major
depression [17, 18].
Self-reported leisure-time physical activity (LTPA)
Participants self-reported their activity patterns using questions based on the Global Physical
Activity Questionnaire [19]. Levels of LTPA were calculated as the minutes per week that par-
ticipants reported participating in moderate-to-vigorous-intensity physical activity (MVPA).
Participants reported the frequency, and duration of physical activity (PA) in a typical week, at
vigorous and moderate intensities, respectively. We summarized the total number of minutes
for PA in each intensity, where minutes spent in vigorous-intensity PA were doubled and
added to the number of minutes of moderate-intensity PA to approximately equivalent the
metabolic equivalent of task value [20]. Cancer survivors were classified as inactive (zero min/
week MVPA), insufficiently active (<150 min/week MVPA), and sufficiently active (150
min/week MVPA) based on the physical activity guidelines for cancer survivors [21].
Statistical analysis
Survey analysis procedures were used to account for the sample weights (MEC weight), stratifi-
cation, and clustering of the complex sampling design to ensure nationally representative esti-
mates. NHANES cancer survivors with complete information on handgrip strength, cognitive
function and other characteristics were included in the analyses. Descriptive characteristics
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were analysed separately in men and women, due to the documented gender difference in
muscle strength [22] and cognitive function during later-life [23]. We summarized weighted
means and standard errors for continuous variables, weighted proportions for categorical vari-
ables, and provided explorative P-values for gender comparison.
Linear regressions were carried out to quantify associations between handgrip strength and
cognitive function test scores. We tested for the interaction of handgrip strength and gender
and found significant terms in linear regression models for both cognitive test scores (both P-
values<0.03). Hence, all analyses were carried out in gender-specific models. The multivari-
able linear regression models were adjusted for age, race, BMI, education level, smoking status,
depressive symptoms and level of LTPA. We examined the normality of residuals by kernel
density estimate and standardized normal probability plots for all the linear regression models.
For explorative purpose, we further adjusted for the handgrip strength squared term in qua-
dratic regressions.
The following sensitivity analyses were conducted: 1) using handgrip strength defined as
the maximal value of dominant hands; 2) using handgrip strength defined as the sum of the
maximal value of both hands in the multivariable regression models, for men and women,
respectively. All statistical significance was set at p<0.05. All statistical analyses were per-
formed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 434 cancer survivors had sufficient data on two cognitive function tests. Of these, we
excluded 38 (9%) participants who did not have complete data on handgrip strength. We fur-
ther excluded13 (3%) participants who did not provide information on other characteristics.
Our analysed sample consisted of 383 cancer survivors (mean age = 70.9 years, mean
BMI = 29.3 kg/m2) with detailed data for analyses. Prevalent cancer types were breast (22.9%),
prostate (16.4%), colon (6.9%) and cervix (6.2%). There were more female (58.5%) than male
cancer survivors in our sample. We observed no statistically significant differences between
men and women for most characteristics, except for women being more likely to live alone (P-
value <0.001), more likely to be non-smoker (P-value = 0.02) and more likely to have mild or
clinically relevant depression (P-value = 0.01) than men (Table 1). There were also no statisti-
cally significant associations between handgrip strength defined sarcopenia (P-value = 0.07) or
test scores on AFT (P-value = 0.07) and DSST (P-value = 0.48). Women had significant lower
handgrip strength (24.0 vs. 39.8 kg, P-value<0.001) compared to men.
Associations between handgrip strength and cognitive function
Table 2 summarizes both the unadjusted and adjusted associations between handgrip strength
and cognitive function test scores. For men, high handgrip strength was associated with higher
scores in both AFT and DSST in un-adjusted linear regression models. However, in multivari-
able-adjusted linear regression models, associations were attenuated to null. The explorative
quadratic regression indicated an inverted U-shape relationship between handgrip strength
and DSST score in men. Higher handgrip strength was associated with better DSST score
among men, which peaked at handgrip strength of 40–42 kg. Following handgrip strength
beyond 42kg, the DSST score appeared to decline. For women, those with higher handgrip
strength performed better in cognitive tests in the unadjusted linear regression model, and
these findings were maintained in multivariable analyses. Among women, each increase kg of
handgrip strength was associated with 0.20 (95% CI: 0.08 to 0.32) and 0.83 (95% CI: 0.30 to
1.35) higher scores in the AFT and DSST, respectively. Using 10th and 90th percentiles of gen-
der specific handgrip strength, Fig 1 depicts the fitted linear line and quadratic curve between
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handgrip strength and DSST score in men and women, respectively. We conducted further
analyses restricted to breast cancer survivors (n = 93), because it was the most prevalent cancer
type in our sample. We observed similar associations as we did in the analyses in all women
cancer survivors, yet with slightly larger beta-coefficients. Among breast cancer survivors, each
increase kg in handgrip strength was associated with 0.27 (95% CI: 0.00 to 0.54) higher score
in AFT, and 1.03 (95% CI: 0.55 to 1.51) higher score in DSST.
Sensitivity analyses returned similar results. In women, using the maximal value of domi-
nant hands, each increase kg of handgrip strength was associated with 0.17 (95% CI: 0.05 to
0.28) and 0.77 (95% CI: 0.27 to 1.26) higher scores in AFT and DSST, respectively. While using
the sum of the maximal value of both hands, each increase kg of handgrip strength was associ-
ated with 0.08 (95% CI: 0.01 to 0.14) and 0.40 (95% CI: 0.09 to 0.71) higher scores in AFT and
Table 1. Characteristics of cancer survivors aged 60 years or older from the NHANES (2011–2014), by gender.
Men Women P-values
N 183 200
Age (years) Mean (s.e.) 70.9 (0.6) 70.9 (0.6) 0.99
BMI (kg/m2) 0.27
<18.5 % 0.0 1.8
18.5–24.9 % 21.6 28.7
25.0–29.9 % 37.2 28.7
 30 % 41.2 40.8
Race 0.45
Non-Hispanic White % 84.1 86.3
Non-Hispanic Black % 8.6 6.0
Hispanic and Other % 7.3 7.7
Education 0.28
Less than 12th grade % 9.8 11.0
High School % 19.5 24.6
Some college % 26.6 34.3
College graduate or above % 44.1 29.1
Marital status < .001
Live with someone % 83.0 53.9
Live alone % 17.0 46.1
Smoking 0.02
Never smoker % 34.6 53.1
Former smoker % 55.5 36.0
Current smoker % 9.9 10.9
Depressive symptoms 0.01
None or minimum % 88.0 70.1
Mild % 8.2 23.8
Clinically relevant % 3.8 6.1
Leisure time physical activity (LTPA) 0.11
Inactive % 49.3 63.5
Insufficiently Active % 19.2 12.1
Sufficiently Active % 31.5 24.4
Handgrip strength defined sarcopenia % 10.9 20.4 0.07
The Animal Fluency test Mean (s.e.) 18.7 (0.6) 17.5 (0.4) 0.07
The Digital Symbol Substitution test Mean (s.e.) 50.7 (1.6) 52.5 (1.6) 0.48
https://doi.org/10.1371/journal.pone.0197909.t001
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DSST, respectively. Similar quadratic regression terms were seen in men with inverted U-
shape association when using maximal of dominant hands, whereas no associations were seen
using sum of the maximal value of both hands (data not shown).
Table 2. Associations between handgrip strength and cognitive function from unadjusted and multivariable linear and quadratic regression models among cancer
survivors aged 60 years or older from the NHANES (2011–2014).
Unadjusted
Beta-coefficient (95% CI)
P- values Adjusteda
Beta-coefficient (95% CI)
P- values
The Animal Fluency Test
Men (n = 183) 0.25 (0.09 to 0.41) 0.002 0.14 (-0.02 to 0.31) 0.083
Women (n = 200) 0.34 (0.21 to 0.46) < .001 0.20 (0.08 to 0.32) 0.002
Breast cancer survivors (n = 93) 0.67 (0.14 to 0.68) 0.004 0.27 (0.00 to 0.54) 0.054
The Digital Symbol Substitution Test
Men (n = 183) b 0.63 (0.29 to 0.96) 0.001 2.46 (1.44 to 3.47) < .001
-0.03 (-0.04 to -0.02) c < .001
Women (n = 200) 1.33 (0.91 to 1.74) < .001 0.83 (0.30 to 1.35) 0.003
Breast cancer survivors (n = 93) 1.59 (0.98 to 2.20) < .001 1.03 (0.55 to 1.51) < .001
aAdjusted for age, BMI, race and ethnicity, education, marital status, smoking status, depressive symptoms and level of leisure-time physical activity.
bExplorative analyses fitted a quadratic regression model for the association of handgrip strength and the Digital Symbol Substitution test score in men.
cHandgrip strength squared.
https://doi.org/10.1371/journal.pone.0197909.t002
Fig 1. Gender-specific associations between handgrip strength and the digital symbol substitution test score among
cancer survivors aged 60 years or older from the NHANES (2011–2014).
https://doi.org/10.1371/journal.pone.0197909.g001
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Discussion
In a US nationally representative sample of 383 (weighted size = 7,489,109) cancer survivors,
we investigated the associations of handgrip strength and cognitive function. Our findings sug-
gest that stronger handgrip strength was associated with better performances on cognitive
tests among women cancer survivors age 60 years and older, particularly breast cancer survi-
vors. In men, we observed an inverted u-shape association such that higher handgrip strength
was associated with better cognitive function among those having a lower level of handgrip
strength, and this association reversed beyond handgrip strength of 40–42 kg. These findings
suggest a role of muscle function in cancer and cancer treatment related cognitive impair-
ments, though the drivers of the inverted u-shape association in men are not clear.
To the best of our knowledge, this is the first study to investigate the association of handgrip
strength with cognitive test scores in cancer survivors. Handgrip strength is a non-invasive
measure of physical health that has been widely used in research and clinical settings [24, 25].
Prior studies have established an association between handgrip strength and cognition in
aging cohort studies [26, 27]. Therefore, handgrip strength has been suggested as a useful tool
in geriatric practice in monitoring cognitive function decline [28]. It is worth mentioning that,
although not all, most aging studies used the mental state examination as an outcome measure,
which indicates global cognition [26, 29]. Nevertheless, cognition is a multi-domain concept
that describes the mental process of acquiring knowledge, including aspects such as awareness,
perception, reasoning and judgement [30, 31]. Among cancer survivors, the most commonly
reported cognitive impairments fall in the following domains: executive function (working
memory), and attention and concentration (processing speed) [1]. Therefore, it is of utmost
importance for cognition measures in cancer survivor population to be domain-sensitive to
cognitive impairments related to cancer and its treatment.
Previously often referred as “chemo brain”, cancer survivors experience neuropsychological
difficulties after chemotherapy [32]. Prior aetiological studies have focused on cancer therapy
related risk factors; such that systematic therapy (chemotherapy, radiation, and hormone ther-
apy) agents are thought to accelerate the neurodegeneration and induce hippocampus dys-
function [33]. However, cognitive impairments are not exclusively presented among those
who underwent systemic therapy. The prevalence of detectable cognitive impairments was
about 30% among cancer survivors before starting treatments, higher than their aged matched
cancer-free controls [2], suggesting risk factors other than cancer therapy alone.
A few pathways have been proposed to underlie the complex aetiology of cancer- and can-
cer treatment related cognitive impairments, such astumor biology and poor DNA repair
mechanisms, generally being non-modifiable [2]. Recently work has shown promising results
by demonstrating associations of inflammation, cytokines and growth factors with cognitive
impairments in cancer survivors [34]. One of such markers, lower serum level of BDNF has
been shown to be associated with cognitive impairments in a sample of 59 cancer patients
receiving chemotherapy for metastatic disease [3]. Furthermore, findings from a longitudinal
study of 145 early-stage breast cancer patients suggested that carriers of BDNF Met allele could
protect cancer patients against post chemotherapy cognitive impairment [4]. BDNF is a mem-
ber of the nerve growth factor family of peptides and regulates neuronal development and
plasticity [35]. This finding is important because BNDF could be produced by brain and skele-
tal muscle cell in response to muscle contraction, namely exercise [5]. There have been pilot
studies investigating the impact of exercise on cognitive functions among cancer survivors
[36]. Only one study included pre-treatment data, and none considered muscle function [36].
Such design may overlook the key role of muscle dysfunction in cognitive function because
weakened muscle strength and muscle mass loss is common in cancer survivors, often before
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treatment begins [7]. Up to 20–30% weakened muscle strength has been reported in survivors
of colorectal cancer [37], prostate cancer [38], and breast cancer [39] and linked with worsened
survival [40], surgery complications [40], depression and fatigue [7]. Muscle strength is posi-
tively correlated with serum BDNF concentration [6]. Our findings point to a potential critical
role of muscle dysfunction in cancer- and cancer treatment related cognitive impairments. In
our sample, the prevalence of handgrip strength defined sarcopenia was 10.9% in men
(<30kg) and 20.4% in women (<20kg). This discrepancy in prevalence, although not signifi-
cant (P- value = 0.07), might contribute to the different patterns of association we observed in
men and women. There is no existing evidence to explain the inverted u-shape we have
observed in men. Longitudinal research is needed to explore these gender-related differences
in detail.
There are a number of limitations to this study. First, the cross-sectional nature makes it
impossible to determine a causal association. It is possible that cancer survivors with better
cognitive function were more independent, thus they maintained better physical function,
than those who were cognitively impaired. Thus, the better handgrip strength might be an
indicator of better cognitive function. Second, we were not able to conduct analyses stratified
by time since diagnosis because of the limited number of individual cancers. Third, self-
reported physical activity did not include information on types of activities performed. It is
plausible that different associations exist between activity type and handgrip, likely owning to
the primary muscles engaged in specific activities. Fourth, direct comparisons between the
present study and previous literature in non-cancer survivors cannot be made owing to hetero-
geneity in outcome measures used. Future research needs to be carried out to compare changes
in grip strength between cancer survivors and non-cancer survivors. Finally, the NHANES
study does not query participants’ information on cancer treatment modalities and doses,
which might be associated with muscle dysfunction and cognitive function decline [7, 32].
This should be explored in further studies.
Conclusion
To the best of our knowledge, this is the first study to demonstrate that handgrip strength is
associated with some aspects of cognitive function in cancer survivors. Prospective studies are
needed to address causal inference. Moreover, future studies should incorporate pre-treatment
information on muscle function (muscle strength and body composition), relevant biomark-
ers, and measures on cognition domains that are specific to cancer and its treatment. Ideally,
such studies should be conducted in patients with similar tumor biology and treatment modal-
ity to elucidate the impact of muscle function, a potential modifiable factor in reducing cancer-
and cancer treatment-related cognitive impairments.
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